2b 351

26mar02 16:44:41 User021138 Session D8587.1

Sub account: 6235-59216-ANT-3/26/02

File 351:Derwent WPI 1963-2001/UD, UM & UP=200219 (a) 2002 Derwent Info Ltd *File 351: Please see HELP NEWS 351 for details about U.S. provisional applications.

?e pn=jp 2777678

Ref	Items	Index-	-term
E1	1	PN=JP	2777677
E2	1	PN≖JP	2777677B
E3	1	*PN=JP	2777678
E4	1	PN=JP	2777678B
E5	1	PN=JP	2777679
E6	1	PN=JP	2777679B
E7	1	PN=JP	2777680
EВ	1	PN=JP	2777680B
E9	1	P11=JP	2777681
E10	1	PN=JP	2777681B
E11	1	PN=JP	2777685
E12	1	PN=JP	2777685E

?s €3

S1 1 PN="JP 2777678"

?t s1/ti

1/71/1

DIALOG(R) File 351:(c) 2002 Derwent Info Ltd. All rts. reserv.

Recombinant human leukocyte-derived hepatocyte growth factor - with DNA encoding it, recombinant expression vectors and transformant cells expressing it

?t s1/5

1/5/1

DIALOG(R) File 351: Derwent WPI

(c) 2002 Derwent Info Ltd. All rts. reserv.

003866552

WPI Acc No: 1991-370578/199151 Felated WPI Acc No: 1998-409650

X.F.AM Acc No: C91-159736

Recombinant human leukocyte-derived hepatocyte growth factor - with DNA encoding it, recombinant expression vectors and transformant cells expressing it

Patent Assignee: NAKAMUPA T (NAKA-I); TOYO BOSEKI KK (TOYM)

Inventor: ASAMI O; HAGIYA M; IHAFA I; MAKAMURA T; SAKAGUCHI M; SEKI T;

SHIMIZU S; SHIMONISHI M

Number of Countries: 005 Number of Patents: 008

Patent Family:

Fatent Family:							
Patent No	Kind	Date	Applicat No	Kind	Date	Week	
EP 461560	А	19911318	EP 91109369	А	19910607	199151	В
JP 5111383	А	19930507	JP 91163485	А	19910606	199323	
JP 3777678	В2	199807.13	JP 91163485	А	19910606	199834	
JP 10191991	А	199307.18	JP 91163485	А	19910606	199840	
			JP 9837890	А	19910606		
EP 461560	В1	19931113	EP 91109369	А	19910607	199850	
			EP 98108130	А	19910607		
DE 59130494	Ε	19981224	DE 630494	А	19910607	199906	

```
19910607
                            EP 91109369
                                                19910606 100044
JF 3082171
              B2 20000828
                           JF 91163485
                                          A 19910606
                            JP 9837890
                  20001031 JP 9837890
JP 2000300282 A
                                           A 19910606 100059
                            JP 2000107213 A
                                                19910606
Priority Applications (No Type Date): JP 90152474 A 19900611
Cited Patents: 8.Jnl.Ref; EP 412557; JP 60045534; JP 63022562; WO 9010651
Patent Details:
Patent No Kind Lan Pq
                        Main IPC
                                    Filing Notes
EP 461560
          A
                   33
   Designated States (Regional): DE FR GB IT
JP 5111383 A 23 C12N-015/16
            В2
                   22 C12M-015/09 Frevious Publ. patent JP 5111383
JP 2777678
JP 10191991 A
                   26 C12N-015/09 Div ex application JP 91163485
EP 461560 B1 E
                  C12N-015/19 Related to application EP 98108130
                                    Related to patent EP 859009
  Designated States (Regional): DE FR GB IT
DE 69130494 E C1MH-015/19
                                   Rased on patent EP 461560
           B2
                   25 C13N-015/09 | Div ex application JP 31163485
JP 3082171
                                    Previous Publ. patent JP 10191991
JP 2000300282 A 22 C13N-015/09 Div ex application JP 9837890
Abstract (Basic): EP 461560 A
       A recombinant expression vector capable of expressing, in host
    cells, the base sequence encoding human leukocyte-derived hepatocyte
    growth factor (HGF) is new. Also claimed are: (1) a transformant obtd.
    by transforming mammalian or microorganism cells with the vector; (2)
    prodn. of recombinant human leukobyte-derived HGF by culturing the
    transformant of (1) and harvesting the protein from the culture; and
    (3) a recombinant (esp. single-chain) human leukocyte-derived HGF obtd.
    as in (2).
         Pref. the HGF has an amino acid (AA) sequence corresponding to
    residues 1(Met) to 728(Ser) of a specified 1st sequence (HLC3) or
    residues 1(Met) to 723(Ser) of a 1nd sequence also provided (HLC2).
         USE/ADVANTAGE - The recombinant HGF is expected to be useful for
    heratocyte cultivation, liver regeneration, research into liver
    function, and the effect of various hormones and drugs hepatocytes,
    research into the carcinogenesis mechanism of hepatoma. It may also be
    used to prepare anti-HGF antibodies for use in diagnostics and
    theraphy. Native HGF is secreted only in trace amts, and is difficult
    to obtain. Use of recombinant techniques will allow mass produ. of the
    polypeptide.
        Dwg.0/15
Title Terms: RECOMBINATION; HUMAN; LEUCOCYTE; DERIVATIVE; HEPATO; GROWTH;
  FACTOF; DNA; ENCODE; RECOMBINATION; EXPRESS; VECTOR; TRANSFORM; CELL;
  EXPRESS
Derwent Class: B04; D16
International Patent Class (Main): C12N-015/09; C12N-015/16; C12N-015/19
International Patent Class (Additional): A61R-037/02; A61R-037/24;
  A61K-038/00; A61K-033/18; C07K-013/00; C07K-014/475; C07K-014/52;
  C07K+015/00; C12N-005/10; C12N-018/45; C12P-021/02; C12R-001-91;
  C11N-015/09
File Seament: CPI
### Status: Signing Off...
log::f
       26mar02 16:46:29 User021138 Session D8587.2
       Sub account: 6235-59216-ANT-3/26/02
```

Status: Signed Off. (3 minutes)